Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Neoplasm Metastasis 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 6Nivolumab 3Gemcitabine 3Cisplatin 3Carboplatin 3brigimadlin 2Ramucirumab 2Fluorouracil 2Docetaxel 2Cetuximab 2tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1regorafenib 1pertuzumab 1milademetan 1larotrectinib 1futibatinib 1durvalumab 1cemiplimab 1adagrasib 1Trastuzumab 1TAS-116 1Ritonavir 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Omacor 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × futibatinib × Thoracic × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡